Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 μg

This publication has 44 references indexed in Scilit:

• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
  Diabetes Care, 2012
• Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
  Diabetes Care, 2012
• DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide
  Diabetic Medicine, 2011
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
  The Lancet, 2010
• Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
  The Lancet, 2010
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
  The Lancet, 2008
• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
  Clinical Therapeutics, 2008
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
  Current Medical Research and Opinion, 2007
• Exenatide
  Drugs, 2007
• Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
  Clinical Therapeutics, 2007